Advanced search
Publication Cover
Expert Review of Neurotherapeutics Volume 21, 2021 - Issue 4
Submit an article Journal homepage
4,402
Views
19
CrossRef citations to date
0
Altmetric
Review

Clinical development of valbenazine for tics associated with Tourette syndrome

Robert H. FarberMedical Affairs, Neurocrine Biosciences, Inc., San Diego, CA, USACorrespondence[email protected]
View further author information
,
Angel AngelovMedical Affairs, Neurocrine Biosciences, Inc., San Diego, CA, USAView further author information
,
Kristine KimMedical Affairs, Neurocrine Biosciences, Inc., San Diego, CA, USAView further author information
,
Tara CarmackMedical Affairs, Neurocrine Biosciences, Inc., San Diego, CA, USAView further author information
,
Dao Thai-CuartoMedical Affairs, Neurocrine Biosciences, Inc., San Diego, CA, USAView further author information
&
Eiry RobertsMedical Affairs, Neurocrine Biosciences, Inc., San Diego, CA, USAView further author information
Pages 393-404 | Received 12 Feb 2021, Accepted 02 Mar 2021, Published online: 01 Apr 2021

Citations (19)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Andrea E. Cavanna. (2022) Current and emerging pharmacotherapeutic strategies for Tourette syndrome. Expert Opinion on Pharmacotherapy 23:13, pages 1523-1533.
Read now

Articles from other publishers (18)

Zhengkang Su, Ziru Dai, Fengqing Qin, Hai Zhang, Miaomiao Zheng, Ya Zhu, Zhiqian Tong, Weihong Song & Xi Li. (2023) Valbenazine promotes body growth via growth hormone signaling during zebrafish embryonic development. Toxicology and Applied Pharmacology 477, pages 116674.
Crossref
Karim Makhoul & Joseph Jankovic. (2023) Real-world experience with VMAT2 inhibitors in Tourette syndrome. Journal of Neurology 270:9, pages 4518-4522.
Crossref
Joseph Jankovic, Barbara Coffey, Daniel O. Claassen, Joohi Jimenez‐Shahed, Barry J. Gertz, Elizabeth A. Garofalo, David A. Stamler, Maria Wieman, Juha‐Matti Savola, Eran Harary, Jessica Alexander, Hadas Barkay & Mark Forrest Gordon. (2023) Safety and Efficacy of Long‐Term Deutetrabenazine Use in Children and Adolescents with Tics Associated with Tourette Syndrome: An Open‐Label Extension Study. Movement Disorders Clinical Practice.
Crossref
Kara A Johnson, Yulia Worbe, Kelly D Foote, Christopher R Butson, Aysegul Gunduz & Michael S Okun. (2023) Tourette syndrome: clinical features, pathophysiology, and treatment. The Lancet Neurology 22:2, pages 147-158.
Crossref
Chih-Yi Chou, Julian Agin-Liebes & Sheng-Han Kuo. (2023) Emerging therapies and recent advances for Tourette syndrome. Heliyon 9:1, pages e12874.
Crossref
Christelle Nilles, Andreas Hartmann, Emmanuel Roze, Davide Martino & Tamara Pringsheim. 2023. Motor System Disorders, Part II: Spinal Cord, Neurodegenerative, and Cerebral Disorders and Treatment. Motor System Disorders, Part II: Spinal Cord, Neurodegenerative, and Cerebral Disorders and Treatment 457 474 .
Wenyan Wang, Shilan Lin, Guangying Du, Xinfa Bai, Jing Lu, Liang Ye, Hongbo Wang, Rui Zhang & Jingwei Tian. (2022) 9-Cyclopropylmethoxy-dihydrotetrabenazine and its stereoisomers as vesicular monoamine transporter-2 inhibitors. Future Medicinal Chemistry 14:13, pages 991-1003.
Crossref
Robert B. Kargbo. (2022) Ibogaine and Their Analogs as Therapeutics for Neurological and Psychiatric Disorders. ACS Medicinal Chemistry Letters 13:6, pages 888-890.
Crossref
Davide Martino & James LeckmanVeit Roessner & Aribert Rothenberger. 2022. Tourette Syndrome. Tourette Syndrome 431 446 .
Emily Behling, Luis C. Farhat, Angeli Landeros‐Weisenberger & Michael H. Bloch. (2022) Meta‐Analysis : Efficacy and Tolerability of Vesicular Monoamine Transporter Type 2 Inhibitors in the Treatment of Tic Disorders . Movement Disorders 37:4, pages 684-693.
Crossref
Marco Bortolato, Barbara J. Coffey, Vilma Gabbay & Simona Scheggi. (2021) Allopregnanolone: The missing link to explain the effects of stress on tic exacerbation?. Journal of Neuroendocrinology 34:2.
Crossref
Jessica Frey & Irene A. Malaty. (2022) Tourette Syndrome Treatment Updates: a Review and Discussion of the Current and Upcoming Literature. Current Neurology and Neuroscience Reports 22:2, pages 123-142.
Crossref
Andreas Hartmann, Per Andrén, Cyril Atkinson-Clement, Virginie Czernecki, Cécile Delorme, Nanette Marinette Debes, Natalia Szejko, Keisuke Ueda & Kevin Black. (2022) Tourette syndrome research highlights from 2021. F1000Research 11, pages 716.
Crossref
Andreas Hartmann, Per Andrén, Cyril Atkinson-Clement, Virginie Czernecki, Cécile Delorme, Nanette Marinette Debes, Natalia Szejko, Keisuke Ueda & Kevin Black. (2022) Tourette syndrome research highlights from 2021. F1000Research 11, pages 716.
Crossref
José Fidel Baizabal-Carvallo & Joseph Jankovic. 2022. The Neurobiology of the Gilles De La Tourette Syndrome and Chronic Tics - Part B. The Neurobiology of the Gilles De La Tourette Syndrome and Chronic Tics - Part B 163 201 .
Wenyan Wang, Guangying Du, Shilan Lin, Jing Liu, Huijie Yang, Dawei Yu, Liang Ye, Fangxia Zou, Hongbo Wang, Rui Zhang & Jingwei Tian. (2021) (+)-9-Trifluoroethoxy-α-Dihydrotetrabenazine as a Highly Potent Vesicular Monoamine Transporter 2 Inhibitor for Tardive Dyskinesia. Frontiers in Pharmacology 12.
Crossref
Mark S. Baron. (2021) Lack of Support for the Use of VMAT-2 Inhibitors for the Treatment of Tics in Tourette Syndrome. JAMA Network Open 4:10, pages e2129704.
Crossref
Keisuke Ueda & Kevin J. Black. (2021) A Comprehensive Review of Tic Disorders in Children. Journal of Clinical Medicine 10:11, pages 2479.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.